Mapping of pharmacological space

Expert Opinion on Drug Discovery

Volumn 6, Issue 1, 2011, Pages 1-7

  Nisius, Britta ^a   Bajorath, Jürgen ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Adverse drug effects; Chemical biology; Chemogenomics; Chemoproteomics; Computational methods; Drugtarget networks; Ligandtarget interactions; Pharmacological space; Polypharmacology; Small molecules; Target families

Indexed keywords

LIGAND;

BINDING SITE; BIOINFORMATICS; COMPUTER MODEL; COMPUTER PROGRAM; CONCEPT MAPPING; DATA BASE; DRUG TARGETING; ENZYME SPECIFICITY; PHARMACOLOGY; PRIORITY JOURNAL; REVIEW; SPACE; VALIDATION STUDY;

EID: 78650634633     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2011.533654     Document Type: Review

References (22)

1. Lipinski C, Hopkins A. Navigating chemical space for biology and medicine. Nature 2004;432:855-61
2. Paolini GV, Shapland RHB, van Hoorn WP, et al. Global mapping of pharmacological space. Nat Biotechnol 2006;24:805-15
3. Bajorath J. Computational approaches in chemogenomics and chemical biology: Current and future impact on drug discovery. Expert Opin Drug Discov 2008;3:1371-76
4. Cleves AN, Jain AN. Robust ligand-based modeling of the biological targets of known drugs. J Med Chem 2006;49:2921-38
5. Keiser MJ, Roth BL, Armbuster BN, et al. Relating protein pharmacology by ligand chemistry. Nat Biotechnol 2007;25:197-206
6. Nidhi, Glick M, Davies JW, et al. Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases. J Chem Inf Model 2006;46:1124-33
7. Hert J, Keiser MJ, Irwin JJ, et al. Quantifying the relationships among drug classes. J Chem Inf Model 2008;48:755-65
8. Yildirim MA, Goh K-I, Cusick ME, et al. Drug-target network. Nat Biotechnol 2007;25:1119-26
9. Mestres J, Gregori-Puigjane E, Valverde S, Sole RV. Data completeness -the Achilles heel of drug-target networks. Nat Biotech 2008;26:983-4
10. Mestres J, Gregori-Puigjane E, Valverde S, Sole RV. The topology of drug-target interaction networks: Implicit dependence on drug properties and target families. Mol Biosyst 2009;5:1051-57
11. Oprea TI, Tropsha A, Faulon JL, Rintoul MD. Systems chemical biology. Nat Chem Biol 2007;3:447-50
12. Bender A, Scheiber J, Glick M, et al. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem 2007;6:861-73
13. Scheiber J, Jenkins JL, Sukuru SCK, et al. Mapping adverse drug reactions in chemical space. J Med Chem 2009;52:3103-07
14. Scheiber J, Chen B, Milik M, et al. Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis. J Chem Inf Model 2009;49:308-17
15. Adams JC, Keiser MJ, Basuino L, et al. A mapping of drug space from the viewpoint of small molecule metabolism. PLoS Comput Biol 2009;5:e1000474
16. Keiser MJ, Setola V, Irwin JJ, et al. Predicting new molecular targets for known drugs. Nature 2009;462:175-81
17. DeGraw AJ, Keiser MJ, Ochocki JD, et al. Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs. J Med Chem 2010;53:2464-71
18. Areias FM, Gregori-Puigjane E, Brea J, et al. In silico directed chemical probing of the adenosine receptor family. Bioorg Med Chem 2010;18:3043-52
19. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 2007;6:881-90
20. Peters UW, Schnider P, Mattei P, Kansy M. Pharmacological promiscuity: Dependence on compound properties and target specificity in a set of recent Roche compounds. ChemMedChem 2009;4:680-86
21. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002;1:727-30
22. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006;5:993-96